Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been given an average recommendation of “Hold” by the eleven analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $24.50.

Several analysts have recently issued reports on the stock. Jefferies Financial Group cut shares of Astria Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $30.00 to $13.00 in a research note on Tuesday, October 14th. Citizens Jmp cut Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 15th. HC Wainwright downgraded Astria Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 16th. Citigroup restated an “outperform” rating on shares of Astria Therapeutics in a report on Wednesday, August 13th. Finally, Wedbush set a $13.00 target price on Astria Therapeutics and gave the stock a “neutral” rating in a report on Wednesday, October 15th.

Institutional Investors Weigh In On Astria Therapeutics

Several large investors have recently made changes to their positions in ATXS. Russell Investments Group Ltd. raised its stake in shares of Astria Therapeutics by 10,311.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 3,506 shares during the period. Farther Finance Advisors LLC increased its holdings in Astria Therapeutics by 185.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,557 shares in the last quarter. Brooklyn Investment Group raised its position in Astria Therapeutics by 1,079.6% in the first quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 7,957 shares during the period. AlphaQuest LLC raised its position in Astria Therapeutics by 100.9% in the first quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 7,139 shares during the period. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Astria Therapeutics during the third quarter worth about $98,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Price Performance

ATXS opened at $13.09 on Thursday. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $13.10. The business has a 50-day moving average of $11.21 and a two-hundred day moving average of $7.95. The stock has a market capitalization of $747.24 million, a price-to-earnings ratio of -6.12 and a beta of 0.07.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The company had revenue of $0.71 million for the quarter, compared to analyst estimates of $10.67 million. Equities research analysts anticipate that Astria Therapeutics will post -1.65 earnings per share for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.